0000000000319937
AUTHOR
M. Parellada
Examining the independent and joint effects of genomic and exposomic liabilities for schizophrenia across the psychosis spectrum
The EUGEI project was supported by the European Community’s Seventh Framework Program under grant agreement no. HEALTH-F2-2009-241909 (Project EU-GEI). Dr O’Donovan is supported by MRC programme grant (G08005009) and an MRC Centre grant (MR/ L010305/1). Dr Rutten was funded by a VIDI award number 91718336 from the Netherlands Scientific Organisation. Drs Guloksuz and van Os are supported by the Ophelia research project, ZonMw grant number: 636340001. Dr Arango was supported by the Spanish Ministry of Science and Innovation; Instituto de Salud Carlos III (SAM16PE07CP1, PI16/02012, PI19/024); CIBERSAM; Madrid Regional Government (B2017/BMD-3740, AGES-CM-2); Fundación Familia Alonso and Fundac…
Premorbid Adjustment and IQ in Patients With First-Episode Psychosis: A Multisite Case-Control Study of Their Relationship With Cannabis Use
Abstract Psychotic patients with a lifetime history of cannabis use generally show better cognitive functioning than other psychotic patients. Some authors suggest that cannabis-using patients may have been less cognitively impaired and less socially withdrawn in their premorbid life. Using a dataset comprising 948 patients with first-episode psychosis (FEP) and 1313 population controls across 6 countries, we examined the extent to which IQ and both early academic (Academic Factor [AF]) and social adjustment (Social Factor [SF]) are related to the lifetime frequency of cannabis use in both patients and controls. We expected a higher IQ and a better premorbid social adjustment in psychotic p…
Influence of social cognition as a mediator between cognitive reserve and psychosocial functioning in patients with first episode psychosis
This work was supported by the Carlos III Institute of Health and European Fund for Regional Development (PI08/1213, PI11/01977, PI14/01900, PI08/01026, PI11/02831, PI14/01621, PI08/1161, PI16/00359, PI16/01164, PI18/00805), the Basque Foundation for Health Innovation and Research (BIOEF), the Secretaria d´Universitats I Recerca del Departament d´Economia I Coneixement (2017 SGR 1365), and R&D activities in Biomedicine, Madrid Regional Government and Structural Funds of the European Union (S2017/BMD-3740 (AGES-CM 2-CM)).